Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Yoichi Tanaka, PhD, Kevin Y Urayama, PhD MPH, Makiko Mori, MD, Daisuke Hasegawa, MD PhD, Yasushi Noguchi, MD, Masakatsu Yanagimachi, MD PhD, Dai Keino, MD PhD, Setsuo Ota, MD PhD, Koshi Akahane, MD PhD, Mayumi Hangai, MD, Takahisa Kawaguchi, Masatoshi Takagi, MD PhD, Katsuyoshi Koh, MD, Fumihiko Matsuda, Atsushi Manabe, MD PhD

Blood (2019) 134 (Supplement_1): 1347.

https://doi.org/10.1182/blood-2019-129440

Published: 2019

Journal Articles

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

Koshi Akahane, MD PhD, Zhaodong Li, PhD, Julia Etchin, PhD, Alla Berezovskaya, Evisa Gjini, PhD, Craig E Masse, PhD, Wenyan Miao, PhD, Jennifer Rocnik, PhD, Rosana Kapeller, MD PhD, Jeremy R Greenwood, PhD, Hong Tiv, Takaomi Sanda, MD PhD, David M Weinstock, MD, A. Thomas Look, MD

Blood (2016) 128 (22): 1596.

https://doi.org/10.1182/blood.V128.22.1596.1596

Published: 2016

Journal Articles

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Meixian Huang, MD, Takeshi Inukai, MD, PhD, Keiko Kagami, BD, Masako Abe, BD, Tamao Shinohara, MD, Atsushi Watanabe, MD PhD, Koshi Akahane, MD PhD, Shinpei Somazu, MD, Hiroko Oshiro, MD PhD, Kumiko Goi, MD PhD, Yasuhiro Maeda, MD PhD, Seiichi Okabe, MD PhD, Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2016) 128 (22): 1059.

https://doi.org/10.1182/blood.V128.22.1059.1059

Published: 2016

Journal Articles

Involvement of Allele-Specific Methylation of Asparagine Synthetase Gene in Asparaginase Sensitivity of BCP-ALL

Atsushi Watanabe, MD PhD, Takeshi Inukai, MD, PhD, Minori Tamai, MD PhD, Tamao Shinohara, MD, Shinpei Somazu, MD, Hiroko Oshiro, MD PhD, Koshi Akahane, MD PhD, Kumiko Goi, MD,PhD, Kunio Miyake, PhD, Kevin Urayama, PhD MPH, Kanji Sugita, MD, PhD

Blood (2016) 128 (22): 3966.

https://doi.org/10.1182/blood.V128.22.3966.3966

Published: 2016

Journal Articles

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

Itaru Kuroda, MD, PhD, Takeshi Inukai, MD, PhD, Xiaochun Zhang, MD, PhD, Jiro Kikuchi, Yusuke Furukawa, Atsushi Nemoto, MD, PhD, Koshi Akahane, MD, PhD, Kinuko Hirose, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Hideo Yagita, PhD, Tetsuzo Tauchi, M.D., Yasuhiro Maeda, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 2740.

https://doi.org/10.1182/blood.V118.21.2740.2740

Published: 2011

Journal Articles

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Atsushi Nemoto, MD, PhD, Takeshi Inukai, MD, PhD, Koshi Akahane, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Yasuhiro Maeda, MD, PhD, Tetsuzo Tauchi, M.D., Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 1511.

https://doi.org/10.1182/blood.V118.21.1511.1511

Published: 2011

Journal Articles

Induction of CD33 Expression in B-Precursor ALL by E2A-HLF Fusion Transcription Factor Derived from t(17;19).

Koshi Akahane, MD, Takeshi Inukai, MD, Toshiya Inaba, MD, Hidemitsu Kurosawa, MD, Mikiya Endo, MD, Hiroaki Goto, MD, Nobutaka Kiyokawa, MD, A. Thomas Look, MD, Kumiko Goi, MD, Kanji Sugita, MD, Shinpei Nakazawa, MD

Blood (2005) 106 (11): 851.

https://doi.org/10.1182/blood.V106.11.851.851

Published: 2005

NARROW

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Involvement of Allele-Specific Methylation of Asparagine Synthetase Gene in Asparaginase Sensitivity of BCP-ALL

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Induction of CD33 Expression in B-Precursor ALL by E2A-HLF Fusion Transcription Factor Derived from t(17;19).

Email alerts

ASH Publications

American Society of Hematology

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Involvement of Allele-Specific Methylation of Asparagine Synthetase Gene in Asparaginase Sensitivity of BCP-ALL

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Induction of CD33 Expression in B-Precursor ALL by E2A-HLF Fusion Transcription Factor Derived from t(17;19).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only